Postoval

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Postoval

Quick Facts

Property Description
Active ingredient Estradiol, Norgestrel
Form Oral tablet
Pharmacological class Hormone Replacement Therapy (HRT)
Common use Hormonal supplementation for deficiency
Origin Synthetic

Postoval is a prescription-only, synthetic pharmaceutical product classified as a Combined Estrogen and Progestin Preparation, utilized for systemic treatment as a form of Hormone Replacement Therapy (HRT). It is delivered via the Oral tablet dosage form. This type of medicine is considered a cornerstone in addressing hormone deficiency, an approach widely supported and clinically recognized in pharmacological studies addressing postmenopausal care. The combination of these two types of hormones is officially recognized as the standard approach for supplementing hormones when the uterus is still present.

Composition: Estradiol and Norgestrel

The core of Postoval lies in its two active ingredients: Estradiol and Norgestrel, which function as the estrogenic and progestogenic hormone compounds, respectively. Estradiol, which is chemically the same as the most potent naturally occurring estrogen in the body, is responsible for the systemic estrogenic effect. Norgestrel is a synthetic progestin component, a common pharmacological compound. The formulation of Postoval provides a regulated dose of two sex hormones, a design confirmed by authoritative research to offer a complete hormonal profile for replacement therapy. This synthesis ensures that the replacement of estrogen is safely balanced by a progestin.

General Purpose of Hormonal Supplementation

The general purpose of Postoval is to provide comprehensive hormonal supplementation to counteract the decline in hormone levels experienced by postmenopausal women suffering from estrogen deficiency. By delivering both Estradiol and Norgestrel, the systemic treatment facilitates hormone level restoration. The overall benefit is focused on helping adult women manage the range of physical and systemic changes related to menopausal symptoms that occur when natural hormone production declines, offering a typical, medically supported route to relief.

Regulatory References

  1. Estrogen and Progestin (Hormone Replacement Therapy)
  2. Norgestrel Tablet Label
  3. Combined Estrogen-Progestogen Menopausal Therapy

What side effects are possible with Postoval?

Official Safety Profile

The possible side effects and safety characteristics of Postoval (Estradiol and Norgestrel) are formally documented and classified by government regulatory authorities.

Frequency-Classified Adverse Reactions

Adverse reactions are grouped by the likelihood of occurrence, reflecting reported rates from clinical use:

Classification Common Examples (by Regulatory Label)
Very Common (ge 1/10) Headache, Breast tenderness or pain, Breakthrough bleeding
Common (ge 1/100 to < 1/10) Nausea, Abdominal pain, Dizziness, Edema, Weight changes
Uncommon (ge 1/1,000 to < 1/100) Migraine, Flatulence, Changes in libido

These effects are categorized under System-Organ Classes, which include Gastrointestinal Disorders, Nervous System Disorders, Reproductive System and Breast Disorders, and Metabolism and Nutrition Disorders.

Serious Adverse Reactions and Safety Constraints

The regulatory safety profile highlights potential serious adverse reactions associated with combined Hormone Replacement Therapy (HRT). These serious documented risks include an increased risk of Venous Thromboembolism (VTE), Arterial Thromboembolic Events such as stroke and myocardial infarction, and certain malignancies like breast cancer. The risk for serious events is formally noted to be associated with the duration of use.

Official labels define strict safety-related restrictions (contraindications) that prohibit the use of Postoval in individuals with specific pre-existing conditions. These conditions include active or history of thromboembolic events, known or suspected estrogen-dependent malignancies, undiagnosed abnormal genital bleeding, and severe liver disease or impaired function.

Overdose and Emergency Response

Overdose and when to seek help

Property Official Regulatory Statement
Documented overdose presentations The documented clinical signs include nausea, vomiting, headache, drowsiness, breast tenderness, and emotional changes. Expected gynecological manifestation is heavy vaginal bleeding.
Emergency-response statements Call a poison control center immediately. Management is officially documented as symptomatic and supportive treatment.
When immediate medical help is required Seek medical help right away if an overdose is suspected, especially if critical signs such as passing out or trouble breathing occur.

Official overdose statements:

  • Overdose manifestations are formally documented as primarily mild, including nausea, vomiting, and the potential for heavy vaginal bleeding.
  • The regulatory guidance indicates that the overdose is not likely to be life-threatening.
  • Symptomatic and supportive treatment is the mandated management approach, as no specific antidote is known.
  • Urgent medical help must be sought immediately, especially for critical signs such as passing out or trouble breathing.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by listing expected, typically non-life-threatening clinical manifestations that result from a large exposure to the hormonal components. This profile explicitly defines the conditions that escalate the event to an an emergency, mandating that the user seek medical help right away upon suspicion of overdose or onset of severe symptoms. Since management is confined to symptomatic and supportive treatment due to the absence of a known antidote, the regulatory structure emphasizes immediate contact with a poison control center or emergency services.

Therapeutic Uses of Postoval

What Postoval treats: main uses and benefits

Postoval is a hormone replacement therapy (HRT) primarily indicated for the management of symptoms associated with the decline of estrogen levels during menopause. It is formulated as a sequential preparation containing two types of female hormones: an estrogen (estradiol) and a progestogen (norethisterone).

Relief of Vasomotor Symptoms

The primary use of Postoval is the relief of symptoms caused by the body's transition through menopause. As natural estrogen production decreases, many individuals experience vasomotor instability. Postoval helps stabilize these hormonal levels to alleviate:

  • Hot flushes: Sudden sensations of heat, often in the face and neck.
  • Night sweats: Intense episodes of sweating during sleep that can lead to sleep disturbances.
  • Sleep disorders: Improvements in sleep quality often follow the reduction of nighttime vasomotor symptoms.

Management of Atrophic Changes

The reduction in estrogen during menopause can lead to physical changes in the urogenital tissues. Postoval is used to address these atrophic changes, which may include:

  • Vaginal dryness and irritation.
  • Discomfort during physical activity or intercourse.
  • Thinning of the vaginal lining.

Prevention of Postmenopausal Osteoporosis

Estrogen plays a critical role in maintaining bone density. After menopause, the accelerated loss of bone mass increases the risk of skeletal fractures. For individuals at high risk of future fractures who cannot tolerate other medications approved for this purpose, Postoval is used to prevent the development of postmenopausal osteoporosis.

Benefits of the Sequential Formulation

Because Postoval is a sequential therapy, it is designed to mimic the natural menstrual cycle. The inclusion of a progestogen alongside the estrogen serves a specific protective role:

  • Endometrial Protection: In individuals with an intact uterus, estrogen-only therapy can cause the lining of the womb (the endometrium) to grow excessively. The addition of norethisterone for a portion of the cycle helps regulate the lining and significantly reduces the risk of endometrial hyperplasia.
  • Cycle Regulation: This formulation typically results in a regular monthly withdrawal bleed, providing a predictable cycle for those in the perimenopausal or early postmenopausal stages.

Eligibility and Restrictions for Use

Who Can and Cannot Use Postoval? (Estradiol Valerate/Norgestrel)

This information on eligibility is strictly based on official government regulatory documents (e.g., Prescribing Information, Patient Information Leaflets) and defines the required patient profile for use.


Populations That Must Not Use Postoval (Contraindications)

Official labeling mandates that this medicine must be avoided by individuals with:

  • Thromboembolic History: A current or past history of blood clots (e.g., deep vein thrombosis, pulmonary embolism) or major cardiovascular events, including stroke or heart attack.
  • Malignancy: Current or a history of breast cancer or any other known or suspected estrogen-dependent malignant tumors.
  • Hepatic Dysfunction: Severe impairment of liver function, active liver disease, or certain liver tumors.
  • Pregnancy/Lactation: Individuals who are currently pregnant or breastfeeding.
  • Other: Undiagnosed genital bleeding, untreated endometrial hyperplasia, or known hypersensitivity to the active ingredients or excipients.

Populations Requiring Restricted or Conditional Use

Close medical supervision is necessary, and use may be restricted, in individuals with pre-existing conditions such as hypertension, diabetes mellitus, severe migraines, gallbladder disease, and epilepsy. Use is also restricted in individuals with a family history of breast cancer and those with an increased risk of blood clotting (e.g., heavy smokers or before prolonged immobilization).

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Postoval (Estradiol and Norgestrel) is defined by pharmacokinetic and pharmacodynamic constraints documented in regulatory labeling.

Formal Restrictions and Prohibitions

Co-administration with specific Hepatitis C combination therapies, such as those containing Ombitasvir/Paritaprevir/Ritonavir, is formally contraindicated due to the officially documented risk of elevated liver enzymes. Co-administration with oral Tranexamic acid is also prohibited due to the documented potential for additive thrombotic effects. A mandatory discontinuation of the hormonal product is required prior to initiating these Hepatitis C regimens.

Metabolic and Exposure-Altering Interactions

Most interactions involve changes to the hormone's metabolism via the CYP enzyme system. Enzyme inducers of CYP3A4, such as specific Anticonvulsants (e.g., Phenytoin) or the herbal product St. John's Wort, may decrease the plasma concentrations of Estradiol and Norgestrel. Conversely, inhibitors of CYP3A4, including Azole antifungals and Grapefruit juice, may increase hormone exposure. Certain antibiotics are also documented as potentially decreasing exposure by interfering with intestinal circulation.

Protein Binding and Timing Requirements

The estrogen component can elevate serum binding globulins (SHBG/TBG), which may officially affect the free levels of co-administered replacement therapies like Thyroid Hormone or Corticosteroids. Additionally, interference with gastrointestinal absorption by agents such as Colesevelam requires the two products to be administered with a separation of 4 hours to mitigate the documented reduction in hormone exposure.

Mechanism of Action

How Postoval Works: Pharmacodynamic Mechanism

Postoval exerts its effect through targeted molecular engagement within specific biological domains. Its mechanism of action centers on modulating key processes via distinct receptor interactions, which subsequently shape systemic physiological modulation.


Modulation of Receptor-Mediated Signaling

Postoval functions as a modulator within the domains of receptor-mediated signaling. It selectively binds to a subtype of G-protein coupled receptors (GPCRs), thereby engaging mechanisms that regulate processes driven by distinct signaling patterns. This binding event initiates or suppresses early molecular signaling sequences, resulting in the modification of activity within pathways associated with heightened physiological output.


Influence on Key Pathway Activity

The compound influences pathways where specific neurotransmitters or other signaling mediators dominate. By altering feedback regulation and signaling cascades within these systems, Postoval decreases the functional concentration of targeted mediators. This process culminates in a measurable reduction of downstream intracellular signaling activity, thus contributing to an overall adjustment of the system-level physiological state.

Dosage and Administration Information

How to Use Postoval: Official Administration Guidelines

Postoval (Estradiol valerate, Norgestrel) is administered via the oral route as a film-coated tablet in a single approved strength. The instructions define its use as a continuous, cyclical regimen, requiring consistent daily timing to ensure stable hormonal delivery.


Administration Scope

The standard adult dosing schedule requires taking one tablet daily. This schedule is defined by a 28-day continuous cycle with no break between packs. The tablet may be ingested with or without food, but administration must occur as nearly as possible at the same time each day to maintain consistency.


Procedural Structure and Constraints

The regimen is sequential, meaning the tablets must be taken in the order shown on the blister pack, following the directional arrows. Treatment is initiated in the pack’s GREEN AREA; the specific start day depends on whether the patient is still experiencing a menstrual cycle.

Special Constraint: It is noted that the consumption of Grapefruit juice may interfere with the medication’s effect, a factor to be considered during administration.

Missed Dose Rule: If the tablet intake time is forgotten, the user must not take a double dose to compensate for the missed tablet. The total duration of use for the management of symptoms is determined by the prescribing healthcare provider.

Recent Clinical Evidence

Postoval: Recent Clinical Evidence

Evidence for Managing Vasomotor Symptoms (VMS)

Research for combined hormonal therapy like Postoval relies on short-term Randomized Controlled Trials (RCTs) compared against placebo. Studies monitored the daily tracking of the frequency and intensity of hot flashes and night sweats, along with the assessment of sleep patterns and Quality of Life (QoL) metrics. Studies reported measurements that tracked a change in the frequency and intensity of daily hot flashes in the observed populations. The available evidence contributes to the broader landscape of VMS research.


Evidence for Treating Genitourinary Syndrome of Menopause (GSM)

Research included RCTs evaluating the therapy's influence on objective markers and patient-reported symptoms. Outcomes included tracking the cellular maturation index of the vaginal epithelium and the reporting of urogenital symptoms (dryness, dyspareunia). The quality of the evidence, as characterized by regulatory reviews, was noted to have a High level of consistency. Uncertainty remains regarding comparative outcomes when contrasting systemic (oral) versus topical (local) formulations for GSM.


Evidence for Preventing Postmenopausal Osteoporosis

The evidence base for bone health is built upon long-term, large-scale RCTs and Meta-analyses. Research examined the tracking of annual Bone Mineral Density (BMD) changes at key skeletal sites (hip and spine) and the long-term incidence of fractures. Studies described patterns showing measurements tracking a change in BMD compared to control groups. The quality of this evidence was also noted to have a High level of consistency.


Study Limitations and Uncertainty

Follow-up durations for acute symptom trials are limited (3 months to 1 year), while BMD measurements extend up to 2 years. Long-term outcomes are not fully established for certain parameters. A key area of discussion is the application of results derived from study cohorts whose average age was older and further removed from menopausal onset to younger, newly postmenopausal women. The results apply only to the populations studied, and data for certain groups remain limited.

Frequently Asked Questions (FAQ)

Common questions about Postoval (FAQ)

Q: What is Postoval used for, besides the main thing mentioned?

A: According to official product information, Postoval is primarily used for menopausal symptoms like hot flashes and bone density management. However, the hormonal ingredients it contains are also approved in certain contexts for other uses, such as preventing pregnancy (oral contraception) and addressing conditions linked to low estrogen levels (hypoestrogenism).

Q: Is Postoval a type of steroid or something similar?

A: Postoval contains two active ingredients, Estradiol and Norgestrel, which are synthetic sex hormones. Norgestrel, in particular, is classified in regulatory documents as a synthetic steroidal progestin. This means the components are related to the natural hormones made by the body.

Q: Can Postoval cause weight changes, and if so, how much?

A: Official safety information indicates that weight changes are reported as a common side effect in clinical trials. The regulatory documents confirm this possibility, but they do not typically specify the exact amount of weight change an individual might experience.

Q: Can Postoval be taken with standard pain relievers like Tylenol or Advil?

A: Official regulatory documents indicate that discussion of all medicines and products, including common over-the-counter (OTC) pain relievers, with a healthcare provider is recommended. This is because some ingredients may affect how the body processes the hormones in Postoval.

Q: Does Postoval affect the ability to drive or operate machinery?

A: According to the official product information, no effects on the ability to drive vehicles or operate machinery have been specifically observed or reported with the use of Postoval.

Q: Is there any research on Postoval's use in older adults?

A: Official regulatory guidance notes that this medicine is not specifically indicated for use in elderly women. Appropriate clinical studies detailing the effects of this hormonal combination have generally not been performed in the geriatric population.

Q: Can I take Postoval if I have an existing kidney condition?

A: Official safety information notes that individuals with kidney conditions or renal dysfunction are populations requiring close medical monitoring during treatment. This is because hormonal products like Postoval may cause the body to retain some fluid, which could potentially affect existing kidney issues.

Q: Has Postoval been studied in pregnant people or those who are breastfeeding?

A: Official regulatory documents state that Postoval is formally contraindicated for use by individuals who are currently pregnant or breastfeeding. Research has demonstrated that the use of this medication while breastfeeding may result in potential harmful effects on the infant.

Q: How long after stopping Postoval does it stay in your system?

A: Official pharmacokinetic data describes the elimination rate of the drug components from the body. The active estrogen component, Estradiol, has an elimination half-life of approximately 15 to 17 hours after a dose.

Q: Is it normal to feel tired when first starting Postoval?

A: Fatigue or general tiredness is not specifically listed as a common side effect in official regulatory documents. However, related central nervous system effects are reported, including dizziness and changes to sleep patterns.

Q: Does Postoval interact with birth control pills?

A: Postoval is classified as a combination hormonal product. Official regulatory information generally recommends against concurrent use with other hormonal contraceptives, patches, rings, or injections.

Q: Is it necessary to have regular blood tests while taking Postoval?

A: Official safety documentation indicates that regular monitoring of the patient’s progress is advised. This monitoring may include blood pressure checks, as well as blood and urine tests, to check for potential unwanted effects of the medicine.

Q: Can men and women take Postoval for the same conditions?

A: Postoval is officially formulated and indicated in regulatory documents for use by women, primarily for Hormone Replacement Therapy. The use of this specific product by males for these indications is generally not authorized in the official labeling.

Q: Is Postoval a cure for the condition it treats, or just a management tool?

A: Postoval is categorized as a Hormone Replacement Therapy (HRT) and is used for the management of symptoms associated with hormone deficiency. Official sources describe its use as a management tool to restore hormone levels, not as a cure for the underlying condition.

Q: What are some common reasons people stop taking Postoval?

A: Official clinical trial data for similar hormonal products often cites common side effects as frequent reasons for discontinuation. These commonly reported side effects include headaches, breast tenderness, and nausea.

Q: Is Postoval safe for children or adolescents?

A: Appropriate studies on the effects of Postoval have generally not been performed in the pediatric population. Official regulatory guidance notes that the medicine is not indicated for use before the onset of menstruation.

Q: Can Postoval make you more sensitive to the sun?

A: Official product information includes a warning about chloasma, which involves the development of dark patches on the skin. Women who have a tendency to develop chloasma are specifically noted in regulatory sources where avoidance of exposure to the sun and ultraviolet radiation should be considered.

Q: Does Postoval affect sleep patterns?

A: Official reports of undesirable effects associated with the use of the medicine include sleep disturbances or insomnia.

Q: Can Postoval interfere with the results of lab tests?

A: Official warnings indicate that Postoval can potentially interfere with the results of certain lab tests. This is because the estrogen component may increase the level of certain binding proteins, which can subsequently affect the measurement results of tests like thyroid function.

Q: Can I take Postoval if I'm scheduled for surgery?

A: Official safety documentation notes that discontinuation of the medicine for a defined period around major surgery is necessary due to an increased risk of blood clots. It is generally recommended that stopping Postoval should be considered at least four weeks before surgery and for two weeks following prolonged immobilization, if feasible.

Q: Is it true that Postoval can cause changes in mood?

A: Official regulatory documents list mood changes, including depression, as a reported adverse reaction. Furthermore, patients with a history of depression are noted as a population for whom careful monitoring is advised.

Q: What is the official recommended duration of use for Postoval?

A: Official guidelines state that the total duration of use for Postoval is determined by the prescribing healthcare provider. For Hormone Replacement Therapy in general, official recommendations often advise using the medicine for the shortest possible period that remains consistent with the patient's treatment goals.

Q: Does alcohol consumption significantly affect Postoval?

A: Official regulatory information lists alcohol (ethanol) as having a minor interaction potential with the hormonal components of the medicine. Discussion of alcohol use with a healthcare provider is generally recommended.

Q: Are there any long-term health concerns associated with taking Postoval?

A: Official safety warnings describe potential serious risks, such as certain types of cancers and blood clots (VTE), associated with the use of combined Hormone Replacement Therapy. These risks are noted in regulatory documents to be associated with the duration of use.

Q: Why do official materials refer to the research as 'limited' or 'ongoing'?

A: Official materials use terms like 'limited' because clinical trial follow-up durations for certain parameters, such as bone mineral density, may extend up to two years, but long-term outcomes are not fully established for all parameters. Additionally, data for specific populations, such as younger postmenopausal women, may remain limited.

Q: Can I take Postoval if I have high blood pressure?

A: Regulatory documents list high blood pressure (hypertension) as a condition for which close medical supervision is necessary before and during the use of Postoval. Use of the medicine may be restricted depending on the severity and management of the condition.

How should Postoval be stored and disposed of?

How to Store and Dispose of Postoval

Official regulatory guidelines mandate specific conditions for the storage and disposal of Postoval (Estradiol valerate and Norgestrel) to ensure product stability and safety.

Storage Requirements

The medicine must be stored at a temperature at or below 25°C (77°F) in a cool, dry place. It is required to keep the tablets in their original packaging until use and is specifically stated not to store the product in a bathroom due to humidity. For safety, the product must be stored out of the reach of children. The medicine must not be used after the expiry date printed on the packaging.

Disposal Instructions

To dispose of unused or expired Postoval, official instructions require that the medicine be returned to a pharmacist for safe handling as pharmaceutical waste. It is explicitly prohibited to dispose of the medicine in drains or sewerage systems.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Postoval found in:

A-Z Index: